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patient with a prior vena cava ligation for invasive
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Renal cell carcinoma can involve the inferior vena cava and extend into the right atrium. Cure is rarely achieved in patients
with concomitant metastases, but cytoreductive nephrectomy and eradication of the entire tumor thrombus can extend
survival and prevent symptoms of venous congestion; however, the invasive nature of the tumor thrombus can make
resection with negative margins difﬁcult. We present a patient with aggressive renal cell carcinoma that demanded an iliac
vein-to-right atrium bypass after inferior vena cava ligation during a previous attempt at curative resection with ne-
phrectomy and caval thrombectomy. (J Vasc Surg Cases 2015;1:6-8.)Renal cell carcinoma (RCC) is a locally invasive cancer
that can progress to involve the inferior vena cava (IVC)
and even the right atrium. Despite this aggressive pattern
of invasion, surgical resection with negative margins allows
for a 5-year overall survival that can approach 65% in
patients without distant metastases.1 For patients with met-
astatic disease, in addition to palliative treatment, cytore-
ductive nephrectomy is associated with an extended
median survival.2 Eradication of the tumor burden can
demand not only a radical nephrectomy but also a tumor
thrombectomy using cardiopulmonary bypass (CPB).3
Given the complex nature of these neoplasms, preoper-
ative planning before embarking on surgical resection is
crucial. We present a case of an aborted RCC resection
mandating an infrarenal caval ligation at another hospital,
which was successfully treated at our institution with an
iliac vein-to-right atrium bypass. Explicit consent was
obtained from the patient to publish the material included
in this report.
CASE REPORT
A 69-year-old woman with locally advanced RCC presented
to our urology clinic after having undergone embolization of her
tumor, radical right nephrectomy, and partial IVC resection atthe Division of Cardiac Surgery,a Division of Vascular Surgery and
dovascular Therapy,b and Brady Urological Institute and Department
Urology,c The Johns Hopkins Hospital.
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://dx.doi.org/10.1016/j.jvsc.2014.08.001another hospital. According to operative reports, the tumor
thrombus was densely adhering to the IVC wall and, therefore,
could not be safely resected. Accordingly, the infrarenal vena
cava was stapled after unsuccessful retrieval of the more superior
component of the malignant thrombus. She was given adjuvant
sunitinib but had to stop due to a number of adverse effects,
most notably, hypertension. As a result, the patient suffered from
progressive ascites and bilateral lower extremity edema totaling a
body weight gain of 60 pounds in 2 months.
A computed tomography scan obtained during her evaluation
demonstrated a hyperenhancing mass extending from the nephrec-
tomy surgical bed to the inferior cavoatrial junction. Multiple bilat-
eral pulmonary nodules were also evident. Owing to involvement
of the hepatic veins with thrombus, there were perfusion changes
compatible with hepatic congestion that correlated clinically to her
signiﬁcant ascites (Fig 1).
Her treatment options included continued chemotherapy
with systemic anticoagulation and a palliative care consultation
or aggressive resection and IVC reconstruction. She opted for
the latter and was taken to the operating room for residual tumor
thrombectomy and iliac vein-to-right atrium bypass. The right iliac
artery and vein were circumferentially dissected. The tumor mass
was easily identiﬁed in the retroperitoneum and behind the liver.
The mass was adherent to the liver, hepatic vessels, and retroperi-
toneal soft tissue structures and, thus, was deemed unresectable.
The right external iliac vein was opened, and an 8F Fogarty
balloon catheter was introduced for direct thrombectomy of the
femoral vein. A 12-mm polytetraﬂuoroethylene (PTFE) graft was
sewn to the external iliac vein and an 8-mm Dacron (DuPont,
Wilmington, Del) chimney to the iliac artery for additional venous
drainage and arterial inﬂow, respectively, during CPB. CPB was
instituted and the patient cooled to 25C.
Owing to dense adhesions between the liver and the retroper-
itoneum, the right atrium was opened to facilitate tumor extrac-
tion, with careful attention to clear the hepatic veins to mitigate
the patient’s progressive ascites. For this portion of the operation,
we used short periods of low-ﬂow bypass with vacuum-assisted
drainage to facilitate exposure of the vena cava. A Coda balloon
catheter (Cook Medical, Bloomington, Ind) was used to remove
Fig 1. Computed tomography (CT) scan after the initial operation. Residual tumor thrombus is visible in the
retrohepatic inferior vena cava (IVC; arrow).
Fig 2. A,Distal anastomosis to the right atrium. B, Completed iliac vein-to-right atrium bypass. Note the course of the
conduit over the dome of the liver. The solid arrow denotes the right atrial anastomosis, and the clear arrow denotes the
iliac vein anastomosis.
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graft was sewn to the right atrium in an end-to-side fashion and
tunneled laterally across the dome of the diaphragm and into the
retroperitoneum (Fig 2). The distal aspect of the graft was sewn
to an additional 16-mm PTFE graft into which a Celect IVC ﬁlter
(Cook) had been deployed and secured with 4-0 Prolene (Ethicon,
Somerville, NJ) suture to prevent future embolic phenomenon
(Fig 3). The 16-mm graft was then sewn to the previously created
12-mm right external iliac PTFE graft.
The patient was slowly warmed throughout the venous
reconstruction and was separated from CPB without incident.
Her hospital course was uneventful, her jaundice gradually
resolved, and she was discharged on postoperative day 8. Overthe ensuing 2 to 3 months, the patient reported complete resolu-
tion of her abdominal and lower extremity edema.
She continued sunitinib therapy, but due to progression of her
metastatic foci, was enrolled in a clinical trial 4 months postopera-
tively. She was alive 8 months after her second operation and has
not experienced subsequent ascites or lower extremity swelling.
Furthermore, the patient states that her recovery is back to its base-
line and reports a fully independent performance status.
DISCUSSION
Caval tumor extension occurs in 4% to 10% of patients
with RCC, and surgical management of these aggressive
neoplasms can be challenging.4 Caval thrombectomy is
Fig 3. A, Deployed vena cava ﬁlter within the 16-mm polytetraﬂuoroethylene (PTFE) conduit. B, Postoperative
computed tomography (CT) scan after reconstruction. Note the deployed vena cava ﬁlter within the conduit.
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and a complication rate as high as 25%.1 However, patients
who do not undergo surgical resection demonstrate an
expected median survival of only 6.9 months.1,5 Therefore,
in the appropriately selected patient, surgical resection
should be strongly considered for curative intent. Options
include primary venorrhaphy, patch or interposition graft-
ing, and in certain instances, caval ligation.4,6-8
Given this patient’s substantial tumor burden and the
ﬁbrosis resulting from her previous operation, a complete
IVC resection with tumor excision was not feasible. In
addition, because she had documented pulmonary disease,
heroic resection would likely result in minimal oncologic
beneﬁt. Accordingly, to ameliorate her hepatic and lower
extremity congestion, an external iliac vein-to-right atrium
bypass was performed with PTFE.
Successful reconstructions for central vein stenosis and
malignant superior vein cava syndrome have been
described in small series, but a complete bypass of the
IVC after prior ligation has not been reported.9,10 Tumor
clearance was facilitated via a right atriotomy, which was
then incorporated into the distal anastomosis. Rather
than use hypothermic circulatory arrest, we decided to
use low-ﬂow CPB, which allows for air handling and avoids
deep hypothermia and its associated coagulopathy.
CONCLUSIONS
This technique for reconstruction should not be used
in all patients; however, it provides a safe method of recon-
stituting venous drainage from the lower extremities in
salvage situations in patients who must undergo IVC liga-
tion. Patient selection is therefore a key element in the
workup for this aggressive surgical approach. Accordingly,
caval reconstruction should only be pursued in individuals
with acceptable baseline functional status and a relatively
stable oncologic burden. Symptomatic control via reconsti-
tution of venous ﬂow can allow patients to receive adjuvant
systemic therapy with new biologic agents, which offer thebest opportunity for improvement in survival. Lastly,
because this patient cohort is at high-risk for venous
thrombosis and subsequent embolic phenomenon, place-
ment of a ﬁlter within the bypass graft should be strongly
considered.
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